• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Switzerland·Healthcare·VBSN.SW
Share

IVF Hartmann Holding AG Stocks

CHF 131Last Updated 27.08.2026

Issuer Rating

5/7
Performance

Strong

Risk

Considerable

Recommendation

Hold

Market Cap

CHF 404.30M

CHF 131
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

IVF Hartmann Holding AG provides medical consumer goods in Switzerland and internationally. The company offers medical devices; hygiene products, body care, hair care, and breast feeding aids; and disinfectants. It also provides household items, including film products, hygiene papers, catering supplies, cleaning papers and textiles, and other household items. The company was formerly known as IVF and changed its name to IVF Hartmann Holding AG in 1993. The company was founded in 1870 and is headquartered in Neuhausen am Rheinfall, Switzerland. IVF Hartmann Holding AG operates as a subsidiary of Paul Hartmann Finance B.V.

Company Valuation

Greatly undervalued
7/7

Based on key historical and expected multiples, the stock is undervalued relative to its peers. In particular, the stock is underpriced on P/E, 'cheap' on EV/EBITDA, unde

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

28.08.2026 23:34

"Worsha was seen as a hawk": The market sharply raised expectations for a rate hike in September

28.08.2026 21:40

"The Schrodinger's Cat Situation": Analysts Take Stock of Six Months of the U.S.-Iran War

28.08.2026 20:58

BioNTech and Roche have halted a cancer vaccine trial. What does this mean for the industry?

28.08.2026 19:14

The Fed "has a lot of work ahead" if inflation doesn't come down quickly — Warsh

28.08.2026 19:05

"The Main Focus for the Markets": What to Expect from the Fed Chair's Speech in Jackson Hole

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026